Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Inclusion Criteria: * Histologically-proven intrahepatic cholangiocarcinoma previously treated by first-line systemic therapy * Absence of extra-hepatic metastasis or peritoneal carcinomatosis (as demonstrated by CT-scan) * General health status : World Health Organization Performance Status = 0, 1 * Estimated life expectancy \> 3 months * Disease that is not suitable for resection with a curative intent, as validated by a multidisciplinary committee with at least one senior hepatic surgeon * At least one measurable lesion according to RECIST 1.1 criteria * Platelets ≥100,000/mm3, polynuclear neutrophils ≥ 2000/mm3 , hemoglobin 9g/dL (even transfused patients can be included) * Creatininemia \< 1.5 mol/L * Creatinine clearance \> 30 mL/min * Bilirubinemia ≤2 N (after biliary drainage if necessary) * Aspartate and Alanine Transaminase ≤ 5 mol/L * Reference hepatic MRI (according to the foreseen protocol) done during the 30 days preceding the 1st cycle of treatment * Written informed consent * National health insurance cover Exclusion Criteria: * Patients with cholangiocarcinoma of the gallbladder or common bile duct or those with hepatocholangiocarcinoma or a Klatskin tumor * Patients who are eligible for surgical resection or liver transplantation * Extra-hepatic metastases (Pulmonary micronodules \<7mm without uptake on positron emission tomography are not a contra-indication) * Presence of clinical ascites * History of intra-arterial therapy or more than one line of syst…